Journal: Cell Biology and Toxicology
Article Title: HSP27/IL-6 axis promotes OSCC chemoresistance, invasion and migration by orchestrating macrophages via a positive feedback loop
doi: 10.1007/s10565-024-09983-1
Figure Lengend Snippet: HSP27/IL-6 establishes a positive feedback loop between OSCC cells and M2 TAMs. A - B iNOS, IL-12, TNF-α, Arg-1, IL-10, and IL-6 mRNA levels in RAW264.7cells under stimulation with the TCM of the CAL27 cells pretreated without or with HSP27–siRNA, detected by RT-qPCR. C - D iNOS, IL-12, Arg-1, CD163, and IL-6 mRNA levels in RAW264.7cells pretreated without or with rhHSP27 (2 μg/mL) in the presence of CAL27-CM for 12 h, detected by RT-qPCR. E – F IL-12, Arg-1, and IL-6 mRNA and IL-6 protein levels in RAW264.7cells pretreated without or with TAK-242 (1 µM) under the stimulation of rhHSP27 (2 μg/mL) in the presence of CAL27-CM for 12 h, detected by RT-qPCR ( E ) and ELISA ( F ). G - H IL-6 mRNA, protein levels in THP-1 cells with NC-siRNA or HSP27-siRNA induced TCM, detected by RT-qPCR ( G ) and ELISA ( H ). I - J IL-6 mRNA, protein levels in THP-1 cells without or with rhHSP27 (2 μg/mL) stimulated, detected by RT-qPCR ( I ) and ELISA ( J ). K - L IL-6 mRNA, protein levels in RAW264.7 cells with NC-siRNA or HSP27-siRNA induced TCM, detected by RT-qPCR ( K ) and ELISA ( L ). M – N ), IL-6 mRNA, protein levels in Raw264.7 cells without or with rhHSP27 (2 μg/mL) stimulated, detected by RT-qPCR ( M ) and ELISA ( N ). O - P HSP27 mRNA levels in CAL27 cells without or with IL-6 (100 ng/mL) treated ( O ), with TAMs-CM and TAMs-CM with the IL-6R antagonist tocilizumab (TOC, 5 μg/mL) treated ( P ), detected by RT-qPCR. ( Q - S ), HSP27protein levels in CAL27 cells without or with IL-6 (100 ng/mL) treated, with TAMs-CM and TAMs-CM with the IL-6R antagonist tocilizumab (TOC, 5 μg/mL) treated, detected by Western blotting in the whole-cell lysates ( Q ) and ELISA ( R - S ). T - U HSP27 mRNA levels in SCC9 cells without or with IL-6 (100 ng/mL) treated ( T ), with TAMs-CM and TAMs-CM with the IL-6R antagonist tocilizumab (TOC, 5 μg/mL) treated ( U ), detected by RT-qPCR. V-X HSP27 protein levels in SCC9 cells without or with IL-6 (100 ng/mL) treated, with TAMs-CM and TAMs-CM with the IL-6R antagonist tocilizumab (TOC, 5 μg/mL) treated, detected by Western blotting in the whole-cell lysates ( V ) and ELISA ( W - X ). T-tests and one-way ANOVA. Means ± SD of at least three separate experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001
Article Snippet: In specific experiments, cells will be treated with rhHSP27 from R&D Systems (1580-HS), recombinant human protein IL-6 (rhIL-6) from Peprotech (AF-200–06–20), and the IL-6 receptor inhibitor tocilizumab (anti-IL-6R) from Selleck (A2012).
Techniques: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Western Blot